Compare Summit Therapeutics Inc (SMMT) vs Vertiv Holdings Co (VRT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Vertiv Holdings Co — how do they compare? Summit Therapeutics Inc trades at $15.24 (market cap $12.06B), while Vertiv Holdings Co trades at $292.5 (market cap $108.49B). The key difference: Vertiv Holdings Co is far larger — about 9× Summit Therapeutics Inc's market cap, and Vertiv Holdings Co pays a 0.09% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| SMMT | VRT | |
|---|---|---|
Market Cap | $12.06B | $108.49B |
Sector | Health | Technology |
52-Week High | $26.98 | $376.23 |
52-Week Low | $12.55 | $121.82 |
Enterprise Value | $11.39B | $108.72B |
Dividend Yield | — | 0.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $15.23, up 2.42% today, with a bullish technical signal and strong analyst consensus. The stock shows mixed earnings performance but benefits from positive news on ivonescimab's regulatory progress and clinical expansions. Despite negative profitability metrics, investor sentiment is buoyed by a high price target of $38.00 and recent partnership announcements in cancer drug development.
Outlook hinges on FDA approval for ivonescimab by November 2026, offering significant upside if successful. Risks include cash burn, ongoing losses, and fiduciary investigations. The stock presents a high-risk, high-reward opportunity for speculative investors betting on clinical successes.
Vertiv (VRT) trades at $293.04, up 8.49% in the past 24 hours, reflecting strong momentum amid AI infrastructure demand. The stock exhibits a bullish technical trend with support near $278 and resistance at $293. Financially, revenue grew to $10.23B in 2025 with a net income margin of 15.09%, though valuation ratios like P/E of 63.76 suggest premium pricing. Recent quarters show consistent earnings beats, with Q2 2026 EPS of $1.52 exceeding expectations.
Outlook remains positive driven by AI data center expansion, but risks include high valuation sensitivity and legal investigations. Analyst consensus is strongly bullish with a $386.58 price target, indicating 32% upside potential. Investors should weigh growth prospects against elevated multiples and potential headline volatility from ongoing probes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Vertiv Holdings Co
Vertiv is a global leader in critical digital infrastructure, providing essential power, cooling, and IT management solutions for data centers, communication networks, and industrial facilities. As the primary provider of advanced thermal management and liquid cooling systems, Vertiv is a central player in the AI revolution, enabling the extreme density and power requirements of next-generation GPU-driven computing.
Read more on VRT →
